2fzb: Difference between revisions

New page: left|200px<br /><applet load="2fzb" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fzb, resolution 1.50Å" /> '''Human Aldose Reducta...
 
No edit summary
Line 1: Line 1:
[[Image:2fzb.gif|left|200px]]<br /><applet load="2fzb" size="450" color="white" frame="true" align="right" spinBox="true"  
[[Image:2fzb.gif|left|200px]]<br /><applet load="2fzb" size="350" color="white" frame="true" align="right" spinBox="true"  
caption="2fzb, resolution 1.50&Aring;" />
caption="2fzb, resolution 1.50&Aring;" />
'''Human Aldose Reductase complexed with four tolrestat molecules at 1.5 A resolution.'''<br />
'''Human Aldose Reductase complexed with four tolrestat molecules at 1.5 A resolution.'''<br />


==Overview==
==Overview==
In structure-based drug design, accurate crystal structure determination, of protein-ligand complexes is of utmost importance in order to elucidate, the binding characteristics of a putative lead to a given target. It is, the starting point for further design hypotheses to predict novel leads, with improved properties. Often, crystal structure determination is, regarded as ultimate proof for ligand binding providing detailed insight, into the specific binding mode of the ligand to the protein. This widely, accepted practise relies on the assumption that the crystal structure of a, given protein-ligand complex is unique and independent of the protocol, applied to produce the crystals. We present two examples indicating that, this assumption is not generally given, even though the composition of the, mother liquid for crystallisation was kept unchanged: Multiple crystal, structure determinations of aldose reductase complexes obtained under, varying crystallisation protocols concerning soaking and crystallisation, exposure times were performed resulting in a total of 17 complete data, sets and ten refined crystal structures, eight in complex with zopolrestat, and two complexed with tolrestat. In the first example, a flip of a, peptide bond is observed, obviously depending on the crystallisation, protocol with respect to soaking and co-crystallisation conditions. This, peptide flip is accompanied by a rupture of an H-bond formed to the bound, ligand zopolrestat. The indicated enhanced local mobility of the complex, is in agreement with the results of molecular dynamics simulations. As a, second example, the aldose reductase-tolrestat complex is studied., Unexpectedly, two structures could be obtained: one with one, and a second, with four inhibitor molecules bound to the protein. They are located in, and near the binding pocket facilitated by crystal packing effects., Accommodation of the four ligand molecules is accompanied by pronounced, shifts concerning two helices interacting with the additional ligands.
In structure-based drug design, accurate crystal structure determination of protein-ligand complexes is of utmost importance in order to elucidate the binding characteristics of a putative lead to a given target. It is the starting point for further design hypotheses to predict novel leads with improved properties. Often, crystal structure determination is regarded as ultimate proof for ligand binding providing detailed insight into the specific binding mode of the ligand to the protein. This widely accepted practise relies on the assumption that the crystal structure of a given protein-ligand complex is unique and independent of the protocol applied to produce the crystals. We present two examples indicating that this assumption is not generally given, even though the composition of the mother liquid for crystallisation was kept unchanged: Multiple crystal structure determinations of aldose reductase complexes obtained under varying crystallisation protocols concerning soaking and crystallisation exposure times were performed resulting in a total of 17 complete data sets and ten refined crystal structures, eight in complex with zopolrestat and two complexed with tolrestat. In the first example, a flip of a peptide bond is observed, obviously depending on the crystallisation protocol with respect to soaking and co-crystallisation conditions. This peptide flip is accompanied by a rupture of an H-bond formed to the bound ligand zopolrestat. The indicated enhanced local mobility of the complex is in agreement with the results of molecular dynamics simulations. As a second example, the aldose reductase-tolrestat complex is studied. Unexpectedly, two structures could be obtained: one with one, and a second with four inhibitor molecules bound to the protein. They are located in and near the binding pocket facilitated by crystal packing effects. Accommodation of the four ligand molecules is accompanied by pronounced shifts concerning two helices interacting with the additional ligands.


==About this Structure==
==About this Structure==
2FZB is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with NAP and TOL as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Aldehyde_reductase Aldehyde reductase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.21 1.1.1.21] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2FZB OCA].  
2FZB is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=NAP:'>NAP</scene> and <scene name='pdbligand=TOL:'>TOL</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Aldehyde_reductase Aldehyde reductase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.21 1.1.1.21] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FZB OCA].  


==Reference==
==Reference==
Line 17: Line 17:
[[Category: Heine, A.]]
[[Category: Heine, A.]]
[[Category: Klebe, G.]]
[[Category: Klebe, G.]]
[[Category: Sotriffer, C.A.]]
[[Category: Sotriffer, C A.]]
[[Category: Steuber, H.]]
[[Category: Steuber, H.]]
[[Category: Zentgraf, M.]]
[[Category: Zentgraf, M.]]
Line 25: Line 25:
[[Category: tim barrel]]
[[Category: tim barrel]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 10:51:33 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:26:38 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA